University of Manchester spin-out secures £1.75 million investment
20/02/2012
Ai2, a spin-out of the University of Manchester, has secured £950,000 from MTI and £800,000 from the North West Fund for Biomedical, managed by Spark Impact. The company has developed proprietary human protein-like substances that safely and cost-effectively inhibit bacteria, fungi and viruses. The products have the potential to be used to prevent infection on a wide range of commonly used medical devices including urinary catheters, stents, orthopaedic implants and wound dressings. Ai2’s humanised cationic peptides are available for exclusive license.
www.a-i-2.com, source: www.bionow.co.uk
Related News
University of Manchester wants your feedback
10/10/2012
The University of Manchester has a dentistry innovation: a device for the real-time imaging of root canal treatments.... read more >
Fund dedicated to spin-outs
22/03/2012
MTI, the venture capital fund manager that runs the University of Manchester’s UMIP Premier Fund, is raising money for a new fund dedicated to university spin-outs. ... read more >
New antimicrobial coating on the way
14/05/2012
Researchers at the University of Manchester are working on the development of a new antimicrobial catheter coating that will reduce the need for catheter replacement.... read more >
